Bonus Biogroup

Bonus Biogroup EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Bonus Biogroup (BONS.TA) as of Nov 22, 2026 is -26.68. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -21.70 — a change of 22.97% (lower).

EV/EBIT

-26.68

YoY

22.97%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Bonus Biogroup is 2025 -26.68 . EV/EBIT (Enterprise Value to EBIT) of Bonus Biogroup was 2024 -21.70 . It decreases by 22.97% lower compared to the previous year.

The Bonus Biogroup EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-3,273.31 ILS
Jan 1, 2019
-2,888.35 ILS
Jan 1, 2020
-3,105.98 ILS
Jan 1, 2021
-932.92 ILS
Jan 1, 2022
-1,630.16 ILS
Jan 1, 2023
-21.31 ILS
Jan 1, 2024
-21.70 ILS
Jan 1, 2025
-26.68 ILS
The Bonus Biogroup EV/EBIT history
YEAREV/EBITYoY
-26.68+22.97%
-21.70+1.83%
-21.31-98.69%
-1,630.16+74.74%
-932.92-69.96%
-3,105.98+7.53%
-2,888.35-11.76%
-3,273.31+9.11%
-3,000.13+7,829.96%
-37.83-16.07%
-45.08-16.55%
-54.02+963.35%
-5.08-68.74%
-16.25-95.84%
-391.09-87.72%
-3,183.78+110.14%
-1,515.05+4,677.83%
-31.71-834.03%
4.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bonus Biogroup Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Bonus Biogroup's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Bonus Biogroup's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Bonus Biogroup's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Bonus Biogroup grows earnings faster than its peers.

Bonus Biogroup Stock analysis

What does Bonus Biogroup do? The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bonus Biogroup stock

EV/EBIT (Enterprise Value to EBIT) of Bonus Biogroup is -26.68 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Bonus Biogroup changed from -21.70 to -26.68, representing a 22.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Bonus Biogroup since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Bonus Biogroup with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bonus Biogroup

All Key Metrics — Bonus Biogroup